Biogen Loses Patent Battle For MS Drug — Is BIIB Stock A Safe Buy?Investors Business Daily • 06/18/20
Biogen's stock drops toward 8-month low after disappointing Tecfidera patent rulingMarket Watch • 06/18/20
Biogen Reportedly Loses Patent Battle With Mylan — And Shares PlungeInvestors Business Daily • 06/18/20
New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From TreatmentGlobeNewsWire • 06/10/20
Insider Outperformance: Key Takeaways And How To Benefit Significantly From ItSeeking Alpha • 06/08/20
Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in ScienceGlobeNewsWire • 05/28/20
Is Biogen Stock A Buy Following An Unexpected Alzheimer's Drug Delay?Investors Business Daily • 05/21/20
New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) PatientsGlobeNewsWire • 05/18/20